Therapeutic Area

Ophthalmology

Therapeutic area intelligence for Ophthalmology with 13 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 12
Catalysts: 1
Companies: 10

Companies

AbbVie →

Alcon Labs →

Alembic Pharmaceuticals →

FDC LTD →

Genentech →

Kiora Pharmaceuticals →

Assets

Recent signals(12)

RegulatoryJune 21, 2026

FDA Approves Supplement for Fluorescite by Alcon Labs

The FDA has approved a supplemental application for Fluorescite, which contains fluorescein sodium.

StrategyJune 21, 2026

FDA Grants AP Status for Dorzolamide Hydrochloride ANDA205294

The FDA has granted Abbreviated Approval (AP) status for ANDA205294, a generic formulation of Dorzolamide Hydrochloride.

ClinicalJune 20, 2026

Kiora Pharmaceuticals initiates Phase II trial of KIO-301 for late-stage Retinitis Pigmentosa

Kiora Pharmaceuticals is conducting Phase II study to evaluate KIO-301 in late-stage retinitis pigmentosa patients.

ClinicalJune 20, 2026

Study Initiated to Collect Samples for Eye Disease Research

The National Eye Institute is conducting a study to collect biological samples from individuals with Best disease, L-ORD, and AMD to facilitate research on these retinal conditions.

RegulatoryJune 19, 2026

Alembic's ANDA215230 for Brimonidine Tartrate and Timolol Maleate Receives AP Status

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of AP for Alembic's formulation of Brimonidine Tartrate and Timolol Maleate.

ClinicalJune 19, 2026

AbbVie Evaluates XEN63 Gel Stent for Glaucoma via Two Surgical Approaches

A clinical trial is underway to assess the safety and effectiveness of the XEN63 gel stent in glaucoma patients using two different surgical approaches.

ClinicalJune 18, 2026

Genentech initiates study on progression of intermediate age-related macular degeneration

Genentech is conducting a multicenter observational study to assess disease progression in intermediate age-related macular degeneration over approximately 3 years.

CompetitiveJune 17, 2026

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

The Pra-ffd hydrogel demonstrated improved bioavailability and reduced ocular inflammation in preclinical models.

StrategyJune 17, 2026

Roche Presents New Data on Vabysmo and Susvimo at ARVO 2026

New real-world data confirm Vabysmo's effectiveness in drying the retina for nAMD and DME, while Susvimo shows potential for sustained disease control.

RegulatoryJune 7, 2026

FDA Accepts Supplement for VABYSMO by Genentech

The FDA has accepted a supplemental application for VABYSMO (BLA761235) from Genentech.

RegulatoryJune 6, 2026

FDA Accepts Application for COSOPT PF Supplement by THEA PHARMA

The FDA has accepted the supplemental application NDA202667 for COSOPT PF, a glaucoma treatment.

ClinicalJune 1, 2026

Zhuochuming® Trial Evaluates 3+T&E vs 3+PRN in Diabetic Macular Edema

A clinical trial is underway to compare the efficacy of Zhuochuming® using a 3+T&E regimen against a 3+PRN regimen in treating treatment-naïve patients with diabetic macular edema.

Upcoming catalysts(1)

Phase II Readout

Alnylam — Amvuttra

Ocular RNAi expansion beyond ATTR could unlock new franchise for Alnylam.

August 12, 2026 · Phase II

Indications

Retinal Diseases →

Stargardt disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.